Sentence examples for mean headache frequency from inspiring English sources

For pMOH (Table 1), mean headache frequency was 23.3 ± 6.8 days/month and mean intensity 2.95 ± 0.2 (severe pain; all but one participant reported 3).

Headache yesterday is equivalent to 1-day prevalence, and can be predicted from the 1-year prevalence of all headache (45.2%) and mean headache frequency in days/month in those affected (4.2).

From baseline to visit 5, significant decrease was noted in least square (LS) mean headache frequency (from 19.5 to 8.4, p = 0.002), headache severity (from 8.1 to 6.1, p = 0.017), number of analgesics (from 26.9 to 10.4, p = 0.023) and MIDAS scores (from 67.3 to 18.5, p < 0.001).

RESULTS: Mean headache frequency on topiramate and sodium valproate is significantly lower than placebo.

Mean headache frequency was 25 days per month with the mean pain intensity of 7 cm.

Predictors for good outcome was female gender, migraine, triptan overuse and a mean headache frequency of 10 days/month.

For other headache on ≥15 days/month (Table 1), mean reported headache frequency was 24.9 ± 6.8 days/month and mean intensity 2.6 ± 0.6 (moderate to severe).

In patients with previous incomplete relieve to TPM that were randomized to have NTP added, mean monthly headache frequency significantly dropped from a mean of 8.1 (SD 1.6) to 3.8 (SD 1.2) (p < 0.001).

Notably after 56 weeks (5 treatments), onabotulinumtoxinA treatment reduced the mean headache day frequency by 11.7 days in the PREEMPT studies versus a mean reduction of 9.2 days at week 60 in our study.

From a public-health perspective it was substantial: the mean overall reported headache frequency was 3.8 days/month – 1 day in every eight – and mean overall reported intensity was 2.1.

Both groups showed a moderate mean reduction of headache frequency posttreatment of about 20%, but only small numbers of responders (50% frequency reduction).